SHANGHAI, May 22, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that an abstract of the ...
Allogene Therapeutics has announced the publication of two abstracts ahead of the 2025 ASCO Annual Meeting, showcasing their investigational AlloCAR T products for treating cancer. One highlighted ...
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™) ...
Immatics N.V., a clinical-stage biopharmaceutical company, announced that it will present data on its lead cell therapy candidate, IMA203 TCR T-cell therapy targeting PRAME, at the upcoming 2025 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback